1992
DOI: 10.1016/0959-8049(92)90374-b
|View full text |Cite
|
Sign up to set email alerts
|

EGF receptor amplification and expression in human brain tumours

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

2
34
0
1

Year Published

1993
1993
2019
2019

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 93 publications
(38 citation statements)
references
References 18 publications
2
34
0
1
Order By: Relevance
“…EGFR is involved in oncogenic transformation, which can be caused by receptor overexpression, autocrine ligand loops, gene amplification, or activating mutations such as the EGFR type III deletion mutant (EGFRvIII; refs. [5][6][7][8].…”
Section: Introductionmentioning
confidence: 99%
“…EGFR is involved in oncogenic transformation, which can be caused by receptor overexpression, autocrine ligand loops, gene amplification, or activating mutations such as the EGFR type III deletion mutant (EGFRvIII; refs. [5][6][7][8].…”
Section: Introductionmentioning
confidence: 99%
“…A role for PI3'K in tumorigenesis is underscored by the identi®cation of activating mutations in both upstream and downstream components of PI3'K signaling pathways in human cancer. For example, ampli®cation of members of the receptor tyrosine kinase family capable of activating PI3'K such as platelet-derived growth factor receptor (PDGFR) and epidermal growth factor receptor (EGFR) genes have been demonstrated in glioblastoma (Chaanet et al, 1992;Smits and Funa, 1998). Identi®cation of PKB/Akt, a transforming oncogene that causes thymic lymphomas in mice (see above), as a major target of PI3'K signaling further supports the importance of PI3'K/PKB in cancer.…”
Section: Importance Of Pi3'k Signaling In Cancermentioning
confidence: 99%
“…Increased EGFR expression correlates with a poor clinical outcome in patients with cancer of the lung, bladder, oesophagus, breast, cervix and ovary (Hendler et al, 1989;Fox et al, 1994). Only in glial and head and neck tumours has EGFR over-expression been frequently associated with amplification of the gene (Libermann et al, 1985;Chaffanet et al, 1992;Wong et al, 1992), and on tumour cells expression levels can be increased by several orders of magnitude, suggesting the feasibility of therapeutic strategies that exploit the differential levels of EGFR expression on tumours vs normal cells. Like other growth factor receptors on tumour cells, EGFR may represent a suitable target molecule for antibody-driven therapy.…”
mentioning
confidence: 99%